PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

@article{AbouAlfa2011PR104PS,
  title={PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma},
  author={Ghassan K Abou-Alfa and Stephan Lam Chan and Chia-Chi Lin and Elena Gabriela Chiorean and Randall F. Holcombe and Mary Frances Mulcahy and William D. Carter and Kashyap Patel and William R. Wilson and Teresa J. Melink and John C. Gutheil and C. Andy Tsao},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2011},
  volume={68},
  pages={539-545}
}
PR-104 is activated by reductases under hypoxia or by aldo–keto reductase 1C3 (AKR1C3) to form cytotoxic nitrogen mustards. Hepatocellular carcinoma (HCC) displays extensive hypoxia and expresses AKR1C3. This study evaluated the safety and efficacy of PR-104 plus sorafenib in HCC. Patients with advanced-stage HCC, Child-Pugh A cirrhosis, and adequate organ function, were assigned to dose escalating cohorts of monthly PR-104 in combination with twice daily sorafenib. The plasma pharmacokinetics… CONTINUE READING
6 Citations
18 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…